Saturday 17 October 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024. In the quarter to June 2026, revenue fell 94.2%, EPS fell 18.0% and free cash flow grew 13.9%, each against the same quarter a year earlier.
23.47
1.26
−5.10%
Follow BEAM
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | 5 | 4 | 4 | 2 | 4 |
Altman Z-Score |
— | — | — | 9.45 | 4.03 | 1.59 | 2.18 | 0.89 | 5.41 |
P/S ratio |
— | — | 0.00 | 158,970.77 | 98.73 | 42.89 | 5.60 | 32.14 | 19.62 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (5.32) | (0.60) | 2.57 | 1.25 | 3.20 | (0.94) | 5.19 |
P/Operating CF |
— | — | (6.83) | (157.02) | 2,796.89 | (37.76) | 15.66 | (26.73) | (32.92) |
P/B ratio |
— | — | 0.00 | 15.54 | 6.19 | 3.56 | 2.16 | 2.78 | 2.21 |
Price to Tangible BV |
— | — | 0.00 | 15.54 | 6.19 | 3.56 | 2.16 | 2.78 | 2.21 |
EV/Sales |
— | — | 0.00 | 150,692.81 | 82.76 | 27.98 | 2.87 | 21.28 | 11.86 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | (0.77) | (37.78) | (64.75) | 75.68 | (7.28) | (3.89) | (4.80) |
EV/FCF |
— | — | (0.65) | (32.26) | (37.94) | (64.52) | (5.94) | (3.79) | (4.60) |
Quick Ratio |
0.29 | 5.72 | 3.15 | 2.93 | 5.93 | 4.82 | 5.79 | 4.67 | 12.85 |
Current Ratio |
0.29 | 5.79 | 3.24 | 3.01 | 5.96 | 4.89 | 5.89 | 4.82 | 13.09 |
Net Debt/EBITDA |
0.13 | 3.25 | 1.27 | 2.34 | 2.51 | 3.23 | 6.39 | 2.04 | 3.30 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.25) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.04 | 0.27 | 0.05 | 0.11 |
Operating CF/Net income |
0.28 | 0.17 | 0.79 | 0.49 | 0.18 | (0.08) | 1.13 | 0.92 | 4.31 |
Capex/Depreciation |
0.00 | (20.19) | (4.85) | (3.37) | (6.35) | (10.33) | 3.47 | 10.65 | (2.36) |
| 15.38% | 184.70% | 57.17% | (881.16%) | (69.13%) | (37.06%) | (15.46%) | (43.94%) | (8.11%) | |
| (11.46%) | (139.80%) | (56.35%) | (64.45%) | (38.49%) | (20.53%) | (9.46%) | (29.39%) | (6.19%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
193.74% | (83.60%) | (101.50%) | (80.11%) | (32.40%) | (29.35%) | (11.72%) | (46.66%) | (6.27%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 2,112.11 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 303,438.89% | 429,912.50% | 746.64% | 511.48% | 115.80% | 578.67% | 293.12% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 114,183.33% | 123,354.17% | 110.37% | 144.13% | 30.93% | 175.58% | 81.45% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 39,044.44% | 64,083.33% | 84.04% | 138.41% | 26.12% | 189.97% | 67.44% |
Graham Net Nets |
— | — | (2.16) | 0.03 | 0.12 | 0.19 | 0.35 | 0.25 | 0.37 |
Graham Number |
— | — | 91.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (64.47%) | (5.02%) | (7.47%) | (11.07%) | (6.79%) | (18.47%) | (3.50%) |
Free Cash Flow Yield |
— | — | (69.57%) | (2.94%) | (2.21%) | (1.01%) | (8.65%) | (17.45%) | (13.13%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.81 | 0.87 | 4.90 | 0.77 | 1.41 |
Operating CF per Share |
(0.05) | (7.01) | (11.11) | (2.05) | (1.03) | 0.32 | (1.93) | (4.22) | (3.49) |
Capex per Share |
0.00 | (4.53) | (1.93) | (0.35) | (0.73) | (0.70) | (0.44) | (0.11) | (0.15) |
Free Cash Flow per Share |
(0.05) | (11.55) | (13.04) | (2.40) | (1.76) | (0.38) | (2.37) | (4.33) | (3.64) |
Cash per Share |
0.04 | 50.60 | 14.17 | 6.41 | 15.03 | 15.40 | 15.42 | 10.34 | 12.59 |
Shareholders Equity per Share |
(0.08) | (40.57) | (31.04) | 5.25 | 12.87 | 10.48 | 12.72 | 8.91 | 12.52 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.08) | (40.57) | (31.04) | 5.25 | 12.87 | 10.48 | 12.72 | 8.91 | 12.52 |
Free Cash Flow |
(2.71) | (33.42) | (84.52) | (112.10) | (113.08) | (26.42) | (182.93) | (356.19) | (360.05) |
Working Capital |
(5.00) | 122.69 | 65.41 | 205.98 | 1,059.57 | 869.30 | 1,005.48 | 696.08 | 1,171.75 |
Capital Expenditures |
(0.35) | (13.12) | (12.52) | (16.36) | (46.81) | (48.95) | (33.73) | (8.95) | (14.95) |
Net Current Asset Value |
(5.00) | (136.14) | (262.66) | 102.21 | 625.29 | 484.66 | 732.66 | 507.87 | 1,025.87 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 695.44 | 681.54 | 0.90 | 0.80 | 0.09 | 0.14 | 0.11 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.04 | 0.11 | 0.13 | 0.09 | 0.04 | (0.08) | (0.01) | 0.06 |
Cash ROIC |
270.70% | (115.10%) | 77.36% | (20.56%) | (6.31%) | (1.46%) | (8.43%) | (22.48%) | (14.50%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
33,181.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Payables |
4.00 | 4.18 | 7.60 | 7.08 | 6.89 | 8.25 | 5.32 | 2.74 | 7.05 |
Average Assets |
84.50 | 83.51 | 161.56 | 303.89 | 963.07 | 1,408.08 | 1,400.71 | 1,281.77 | 1,292.50 |
Average Common Equity |
(63.00) | (63.20) | (159.25) | 22.23 | 536.15 | 780.11 | 857.40 | 857.44 | 985.95 |
Columns are period end dates